{"title":"Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung cancer in China.","authors":"Yanhui Li, Yafei Shi","doi":"10.1080/14737167.2026.2757896","DOIUrl":"10.1080/14737167.2026.2757896","url":null,"abstract":"<p><strong>Background: </strong>There is a scarcity of pharmacoeconomic information in China regarding utilizing sintilimab as the second-line therapy for squamous non-small cell lung cancer (NSCLC). This study aimed to estimate the cost-effectiveness of sintilimab compared with docetaxel for treating squamous NSCLC in China.</p><p><strong>Methods: </strong>A partitioned survival model was developed using data from the phase III ORIENT-3 trial (NCT03150875), which randomized patients 1:1 to receive sintilimab (200 mg every 3 weeks) or docetaxel (75 mg/m<sup>2</sup> every 3 weeks). Efficacy and safety data, costs and utilities were derived from the trial, the published literature and local databases. Sensitivity analyses assessed model robustness.</p><p><strong>Results: </strong>Sintilimab provided an additional 0.32 quality-adjusted life years (QALYs) at an incremental cost of $2,789.52 versus docetaxel, resulting in an incremental cost-effectiveness ratio of $8,717.25/QALY, below China's 2024 per capita gross domestic product ($12,961.80). Grade ≥3 adverse events included decreased neutrophil count (23.85% with docetaxel vs 0% with sintilimab) and white blood cell count (19.23% vs 0%). Sensitivity analyses confirmed robust results across all willingness-to-pay thresholds.</p><p><strong>Conclusions: </strong>Sintilimab is cost-effective as a second-line therapy for advanced squamous NSCLC in China. Limitations include utility data from the literature rather than trial patients and lack of post-progression treatment details.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fernando Fernandez-Llimos, M Margarida Castel-Branco, Isabel V Figueiredo, Ana C Cabral, Marta Lavrador
{"title":"Current and emerging measures and methods for evaluating medication adherence behaviors.","authors":"Fernando Fernandez-Llimos, M Margarida Castel-Branco, Isabel V Figueiredo, Ana C Cabral, Marta Lavrador","doi":"10.1080/14737167.2026.2760608","DOIUrl":"10.1080/14737167.2026.2760608","url":null,"abstract":"<p><strong>Introduction: </strong>Medication adherence is a key determinant of treatment effectiveness and health outcomes, yet it remains a major challenge in clinical practice and research. As dynamic and multidimensional behavior influenced by cognitive, emotional, and contextual factors, adherence cannot be fully captured by a single measure. This complexity is further amplified in real-world settings characterized by multimorbidity and polypharmacy.</p><p><strong>Areas covered: </strong>This review examines current and emerging methods for measuring medication adherence. It considers the data sources and computation procedures required. These methods were classified into self-report instruments, electronic monitoring systems, administrative pharmacy claims, and group-based trajectory modeling. It discusses their conceptual basis, strengths, and limitations, highlighting how different methods capture distinct dimensions of adherence behavior.</p><p><strong>Expert opinion: </strong>No single method represents a universal gold standard, and adherence measures are not interchangeable. Selection should be guided by the research objective, whether focused on exposure, determinants, or outcomes. Future advances will depend on integrating complementary methods and adopting longitudinal approaches to better reflect the dynamic nature of adherence and support more effective interventions.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-16"},"PeriodicalIF":2.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug acquisition accounts for a minor share of the costs associated with dobutamine-milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia.","authors":"Ryeska Fajar Respaty, Santi Purna Sari, Bambang Widyantoro","doi":"10.1080/14737167.2026.2760016","DOIUrl":"10.1080/14737167.2026.2760016","url":null,"abstract":"<p><strong>Background: </strong>Adding milrinone to dobutamine (dobutamine-milrinone escalation) in cardiogenic shock (CS) is reimbursed for a limited duration under Indonesia's national health insurance, but its cost structure is poorly characterized. This study quantified direct medical charges associated with escalation and the contribution of drug acquisition.</p><p><strong>Research design and methods: </strong>Retrospective cohort of 76 adult CS survivors (20 escalation, 56 dobutamine monotherapy) at Indonesia's national cardiovascular referral center, 2020-2024. Covariate Balancing Propensity Score-based inverse probability of treatment weighting, using pre-treatment covariates, estimated adjusted cost ratios (CR) for intensive cardiovascular care unit (ICVCU) and total hospital costs from institutional billing records.</p><p><strong>Results: </strong>Escalation was associated with higher ICVCU costs (CR 2.711; 95% CI 1.912-3.844; <i>p</i><0.001) and total hospital costs (CR 2.321; 95% CI 1.372-3.929; <i>p</i>= 0.002). Combined inotrope costs represented 4.3% of ICVCU expenditure in the escalation group, versus 30.9% for therapeutic and interventional procedures. Baseline vasoactive-inotropic score correlated with total hospital cost (ρ=0.597; <i>p</i><0.001).</p><p><strong>Conclusions: </strong>Drug acquisition represented a minor share of costs associated with escalation. The findings support consideration of severity- and resource-based reimbursement approaches rather than focusing solely on duration limits for individual inotropes. Interpretation is limited by the retrospective, single-center, survivor-only design.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.","authors":"Chang Cheng, Tong Liu","doi":"10.1080/14737167.2026.2760022","DOIUrl":"https://doi.org/10.1080/14737167.2026.2760022","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the cost-effectiveness of dostarlimab plus chemotherapy in contrast to chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC) from the perspective of healthcare payers in the U.S.A.</p><p><strong>Research design and methods: </strong>An economic evaluation using a three‑state partitioned survival model assessed the cost-effectiveness of dostarlimab plus chemotherapy compared to chemotherapy alone. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) from clinical trials were digitally extracted, and the log‑normal model with network meta-analysis (NMA) was applied at the end of the trial to extrapolate long-term survival. The cost and health utility data were sourced from the published literature.</p><p><strong>Results: </strong>The anticipated expenditure for dostarlimab plus chemotherapy therapy exceeded the cost for chemotherapy alone therapy (366,887.33 USD vs 102,503.32 USD). The estimated utility was also greater compared to that of chemotherapy alone treatment (3.74 QALYs vs 1.90 QALYs). The ICER was 143,856.30 USD/QALY.</p><p><strong>Conclusions: </strong>Dostarlimab plus chemotherapy was cost-effective compared to chemotherapy alone as a first-line treatment for advanced or metastatic NSCLC patients at the WTP threshold of 150,000 USD/QALY in the U.S.A.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An expert-AI co-creation framework for robust health economic simulations.","authors":"Anna Machens, Hendrik Koffijberg, Shiva Faeghi","doi":"10.1080/14737167.2026.2755647","DOIUrl":"https://doi.org/10.1080/14737167.2026.2755647","url":null,"abstract":"<p><strong>Background: </strong>Health economic (HE) evaluations are essential for healthcare decision-making, yet the rapid pace of innovation demands accelerated HE evaluations. Integrating Generative AI (GenAI), particularly Large Language Models (LLMs), into HE simulation modeling offers a promising opportunity to enhance model development efficiency and speed.</p><p><strong>Research design and methods: </strong>We propose a framework for automating HE model development through expert-AI co-creation. This framework enables GenAI to generate simulation models in a structured and transparent manner. The proposed approach is expert-led and incorporates iterative prompt-response cycles. GPT5-mini and GPT-5.2-codex are employed using zero-shot prompting. As LLM results are non-deterministic, we introduced a Prompt Robustness Test (PRT) to assess the stability of LLM-generated outputs, indicating whether a prompt is sufficiently reliable to support automated model development. The methodology is applied to replicate a published discrete-event simulation comparing two post-surgery treatment strategies for colon cancer. The original model is complex and representative of real-world HE practice.</p><p><strong>Results: </strong>Using our framework, we replicated the model in Python, achieving cost and QALY estimates within 2% of the original. While the overall pathway structure was successfully reconstructed, several logic discrepancies remained compared with the original model.</p><p><strong>Conclusions: </strong>Our framework provides methodological guidance on the expert-AI co-creation of complex HE models, emphasizing that expert oversight is essential throughout the process.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma.","authors":"Ying He, Maojin You","doi":"10.1080/14737167.2026.2760014","DOIUrl":"https://doi.org/10.1080/14737167.2026.2760014","url":null,"abstract":"<p><strong>Background: </strong>Phase III trial NCT04560894 showed finotonlimab plus bevacizumab biosimilar SCT510 (FIN-BEV) improved survival over sorafenib in advanced hepatocellular carcinoma (HCC). However, the cost-effectiveness of FIN-BEV relative to sorafenib remains uncertain. This study evaluates the cost-effectiveness of FIN-BEV as a first-line treatment for advanced HCC from the perspective of the Chinese healthcare system, compared to sorafenib.</p><p><strong>Methods: </strong>A partitioned survival model with three health states was built in TreeAge Pro 2022 using NCT04560894 data. Drug costs were calculated based on national bid-winning prices, while other costs and utility values were obtained from published Chinese literature. Sensitivity analyses were conducted to assess the robustness of the model.</p><p><strong>Results: </strong>FIN-BEV yielded 2.43 QALYs at $66,740.79 versus sorafenib's 1.63 QALYs at $14,241.13. The incremental cost-effectiveness ratio was $65,717.80/QALY, exceeding the willingness-to-pay threshold of $27,906/QALY. The probability of FIN-BEV being cost-effective as a first-line treatment for advanced HCC was 0.2%. Key factors influencing the model results included the utility value of progression-free survival, the cost of SCT510, body weight, the utility value of progressive disease, and the cost of finotonlimab.</p><p><strong>Conclusion: </strong>From the perspective of the Chinese healthcare system, FIN-BEV does not represent a cost-effective first-line treatment for advanced HCC when compared to sorafenib.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yara A Alharbi, Yusra I Alghamdi, Jana H Alshaikh, Dana A Alawaji, Reham M Baamer, Alyaa M Ajabnoor, Zuhair A Alqahtani, Abdulrahman A Alsuhibani, Rawan O Almadfaa
{"title":"National long-term trends in benzodiazepine outpatients prescription claims, Medicaid reimbursement, and average reimbursement per prescription in the United States, 2010-2024.","authors":"Yara A Alharbi, Yusra I Alghamdi, Jana H Alshaikh, Dana A Alawaji, Reham M Baamer, Alyaa M Ajabnoor, Zuhair A Alqahtani, Abdulrahman A Alsuhibani, Rawan O Almadfaa","doi":"10.1080/14737167.2026.2757900","DOIUrl":"https://doi.org/10.1080/14737167.2026.2757900","url":null,"abstract":"<p><strong>Background: </strong>Research on long-term prescribing and reimbursement patterns for benzodiazepines in the United States remains limited. This study evaluated trends in utilization, expenditures, and average reimbursement per claim of benzodiazepines in the U.S. from 2010 to 2024.</p><p><strong>Methods: </strong>This observational longitudinal study used data recorded between 2010 and 2024 from the National Medicaid State Drug Utilization database. Utilization was defined as the total annual prescription claims count, expenditure as the annual sum of Medicaid reimbursements, and average gross Medicaid reimbursement per prescription claim as annual expenditure divided by the annual number of prescriptions. Results: Approximately 503 million benzodiazepine prescriptions were recorded, with cumulative Medicaid reimbursement of USD 14.9 billion. Intermediate-acting benzodiazepines were the most frequently utilized, whereas long-acting medications accounted for the largest proportion of Medicaid reimbursement. Annual claims decreased from 46.2 million to 23.9 million, while average reimbursement per prescription increased from USD 17.1 to USD 47.5 over the study period. The largest reported average reimbursement per claim increase was observed for short-acting benzodiazepines, which rose from USD 45.2 in 2018 to USD 183.9 in 2019.</p><p><strong>Conclusion: </strong>Benzodiazepine claims decreased significantly between 2010 to 2024, while reimbursement per claim rose significantly. Total Medicaid reimbursement showed no significant net change.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Potential savings in Medicaid antiseizure medication reimbursement, 2008-2025: persistent brand-name reimbursement despite generic availability.","authors":"Tengizi Mtchedlidze, Jeetendra Sah, Giorgi Modebadze, Pradeep Javarayee","doi":"10.1080/14737167.2026.2757890","DOIUrl":"10.1080/14737167.2026.2757890","url":null,"abstract":"<p><strong>Background: </strong>Despite growing use of generic antiseizure medications (ASMs), brand-name products account for substantial Medicaid reimbursement. We assessed long-term reimbursement trends, potential savings from generic substitution, and patterns following generic entry.</p><p><strong>Research design and methods: </strong>Medicaid State Drug Utilization Data (2008-2025) were linked to RxNorm formulations. Utilization was measured in defined daily doses (DDDs), and reimbursement adjusted to 2025Q4 dollars. Hypothetical pre-rebate savings were estimated using formulation-matched generic rates. Event-study, Laspeyres, and state-level analyses assessed post-entry patterns.</p><p><strong>Main outcome measures: </strong>ASM utilization, reimbursement, brand-name utilization and reimbursement shares, potential savings from generic substitution, and post-entry variation.</p><p><strong>Results: </strong>Reimbursement for 23 ASMs between 2008-2025 totaled $28.0 billion, including $19.1 billion for brand-name medications. Utilization increased 81.0%, while brand-name utilization share fell from 59.7% to 5.8%. Brand-name ASMs represented 70.8% of reimbursement in 2025. Potential pre-rebate savings totaled $5.8 billion, with 75.2% concentrated in five ASMs. Following generic entry, adjusted brand-name utilization and reimbursement declined 83.7% and 85.8%, respectively, among observations retaining brand-name use. Adjusted state reimbursement shares ranged from 9.6% to 60.2%.</p><p><strong>Conclusions: </strong>Despite widespread generic adoption, brand-name ASMs continued to account for substantial Medicaid reimbursement. These findings highlight opportunities to evaluate prescribing and reimbursement patterns where generic alternatives exist.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arif Hakan Önder, Mehmet Mutlu Çatlı, Olgun Keskin
{"title":"Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation.","authors":"Arif Hakan Önder, Mehmet Mutlu Çatlı, Olgun Keskin","doi":"10.1080/14737167.2026.2757915","DOIUrl":"10.1080/14737167.2026.2757915","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors improve outcomes across solid tumors but increase oncology drug expenditure. This study estimated the impact of a predefined nivolumab dose stewardship algorithm on drug utilization, nivolumab drug cost, and vial waste.</p><p><strong>Research design and methods: </strong>We performed a single-center retrospective drug-cost and resource-utilization simulation using real-world data from adults who received nivolumab between 2024 and 2026. Observed dosing was compared with a modeled policy incorporating weight-informed dosing, vial-based dose rounding, and preservation of protocol-mandated fixed-dose regimens. Clinical outcomes and adverse events were not assessed; clinical equivalence was assumed for modeling purposes but not demonstrated.</p><p><strong>Results: </strong>Among 102 patients, median age was 64 years, body weight was 70 kg, and exposure was 9.5 cycles. The modeled policy reduced nivolumab consumption from 432,360 mg to 342,360 mg, saving 90,000 mg (20.8%). Estimated nivolumab drug cost decreased from 221,040,980 TL to 175,029,119 TL, saving 46,011,861 TL. Vial waste decreased from 43,360 mg to 2,000 mg, a 95.4% reduction.</p><p><strong>Conclusions: </strong>This retrospective simulation suggests that a predefined nivolumab dose stewardship algorithm may reduce drug use, drug cost, and vial waste. Prospective studies are required before clinical implementation.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Priscila Madeira da Silva Oliveira, Cid Manso de Mello Vianna, Alfonso Jesus Gil Lopez, Gabriela Bittencourt Gonzalez Mosegui
{"title":"Affordability and relative economic burden of multiple sclerosis biologics in South America: a cross-country analysis of prices, purchasing power and regulatory access.","authors":"Priscila Madeira da Silva Oliveira, Cid Manso de Mello Vianna, Alfonso Jesus Gil Lopez, Gabriela Bittencourt Gonzalez Mosegui","doi":"10.1080/14737167.2026.2757886","DOIUrl":"https://doi.org/10.1080/14737167.2026.2757886","url":null,"abstract":"<p><strong>Background: </strong>High-cost biological therapies for multiple sclerosis (MS) may have lower nominal prices in middle-income countries yet impose greater burden relative to local purchasing capacity. We compared regulatory availability, price transparency and relative economic burden.</p><p><strong>Research design and methods: </strong>We analyzed alemtuzumab, interferon beta-1a, natalizumab and ocrelizumab in Brazil, Colombia, Peru and the United States. Prices were compared in nominal US dollars, purchasing power parity-adjusted international dollars and against minimum wages. Defined daily doses supported standardized comparisons; regimen-based costs used reference dosing schedules. Outcomes included historical marketing authorization, observable prices, wage-based affordability and annual acquisition cost relative to gross domestic product per capita.</p><p><strong>Results: </strong>Historical marketing authorization was documented in all 16 medicine-country combinations (100%), and observable prices were identified in 14 (87.5%). None of the 14 assessable combinations met the adapted regimen-based affordability criterion. Under primary price scenarios, monthly-equivalent burden ranged from 27.2 calendar-day equivalents of statutory minimum-wage income for interferon beta-1a in Peru to 326.2 for alemtuzumab in Brazil. Although US nominal prices were generally highest, purchasing-power and wage adjustment altered country rankings.</p><p><strong>Conclusions: </strong>Historical marketing authorization and lower nominal prices did not imply economic accessibility. Cross-country assessments should integrate purchasing power, wages and regimen-based acquisition costs.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}